CHMP2B and frontotemporal dementia: The most direct evidence comes from the identification of individuals with missense mutations in the ESCRT-III subunit Vps2B who develop neurodegenerative diseases, like ALS and frontotemporal dementia (FTD), both characterized by progressive neuronal accumulation of ubiquitin-positive protein aggregates.